Can you take GLP-1 medications with TRT?
Short answer: there is no labeled contraindication between GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide) and testosterone replacement therapy, and prescribers do combine them — most often in men with obesity, type 2 diabetes, or metabolic syndrome who also have low testosterone. The two interact biologically, but in a complementary way: the 2025 BMC Urology meta-analysis on GLP-1 receptor agonists and testosterone (Orra SH et al., BMC Urology, PMID 41291666) and the 2025 Andrology systematic review of GLP-1 effects on testicular function (Salvio G et al., Andrology, PMID 40105090) both report a modest, weight-loss-mediated rise in testosterone on GLP-1 therapy.
That is not a green light to start either drug. Whether you should be on a GLP-1, on TRT, on both, or on neither is a clinical decision that depends on your weight, glycemic status, symptoms, baseline labs, and what your prescriber sees on follow-up panels. This article walks through what the published evidence does and does not say — so you can have a more informed conversation with the clinician who actually treats you.
For the foundational TRT side of the picture, start with the TRT 101 pillar, the TRT blood work schedule, and the TRAVERSE trial breakdown.
Educational disclaimer — please read: This article is educational content, not medical advice. It does not replace evaluation by a physician who knows your full history. Do not start, stop, or combine GLP-1 medications and testosterone replacement therapy based on this article. Both drug classes are prescription-only and have monitoring requirements your prescriber must direct. If you experience severe abdominal pain, persistent vomiting, signs of pancreatitis, gallbladder pain, vision changes, chest pain, severe headache, breast tissue changes, or suicidal thoughts, seek medical care immediately.
What GLP-1 receptor agonists actually do
GLP-1 receptor agonists mimic glucagon-like peptide-1, an incretin hormone the gut releases after meals. Activating the GLP-1 receptor slows gastric emptying, increases satiety signaling in the hypothalamus, lowers glucagon, and amplifies glucose-dependent insulin release from the pancreas. The clinical effects are weight loss and improved glycemic control.
Tirzepatide adds a second mechanism — it is a dual GIP and GLP-1 receptor agonist, which appears to drive larger average weight loss than pure GLP-1 agonists in head-to-head data. The agents currently most relevant to the men's-health conversation:
- Semaglutide — sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management.
- Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
- Liraglutide — sold as Victoza (diabetes) and Saxenda (weight management); shorter half-life, daily dosing.
- Dulaglutide — sold as Trulicity for type 2 diabetes.
None of these drugs is FDA-approved for treating hypogonadism, and none is approved for raising testosterone. Any testosterone change observed is a downstream effect of weight loss and metabolic improvement — not a labeled indication.
Metabolic hypogonadism: the connection that ties GLP-1s to testosterone
Obesity and type 2 diabetes are independently associated with lower total and free testosterone. The mechanism is a combination of suppressed hypothalamic-pituitary signaling (low LH and FSH for the testosterone level), increased aromatization of testosterone to estradiol in adipose tissue, and reduced sex hormone-binding globulin from hepatic insulin resistance. The pattern — low total testosterone, normal-to-low LH, normal prolactin, often elevated BMI — is what clinicians label functional or metabolic hypogonadism.
The 2025 Andrology systematic review on GLP-1 receptor agonists and testicular dysfunction (Salvio G et al., PMID 40105090) frames the problem cleanly: hypogonadism and infertility are heavily affected by overweight and obesity, and the central treatment lever is weight loss with metabolic improvement. The 2025 Tandfonline review on the male hormone reset (The Aging Male, DOI 10.1080/13685538.2025.2601423) similarly positions weight loss as the upstream intervention before — or alongside — exogenous hormone therapy.
That framing matters because it shifts the question from does this drug raise testosterone to does this drug fix the metabolic state that suppressed testosterone in the first place. The two questions have different answers and different implications for whether you also need TRT.
Do GLP-1s raise testosterone on their own?
The published meta-analytic data say modestly, on average, in men with obesity. The 2025 BMC Urology meta-analysis (Orra SH et al., PMID 41291666) pooled studies on GLP-1 receptor agonist therapy and testosterone, and reported an overall increase in total testosterone in men with obesity. The 2026 Journal of Sexual Medicine review of GLP-1 effects on male reproductive hormones, semen, and metabolic outcomes (PMID 41498523) describes the same direction of effect — increased total testosterone, particularly in men with obesity.
The 2025 Andrology systematic review (Salvio G et al., PMID 40105090) takes a wider view — gonadal, sexual, and reproductive outcomes — and reports a similar net pattern, with the strongest signal in men whose baseline picture matched metabolic hypogonadism. The 2026 Andrology systematic review on GLP-1 and SGLT2 effects on male sexual hormones (Corona G et al., PMID 42011503) places these findings in the broader context of metabolic medicine.
Several caveats are worth holding in mind:
- Effect sizes vary widely between studies. Average changes are modest. Some trials show meaningful increases, others minimal change. Heterogeneity is high across the meta-analytic literature.
- Most evidence is in men with obesity or type 2 diabetes. Lean, eugonadal men have not been the population studied. Generalizing the testosterone signal beyond men with metabolic disease is not supported.
- Calculated free testosterone can move differently from total testosterone because SHBG often rises with weight loss. The Tandfonline 2025 review (DOI 10.1080/13685538.2025.2601423) walks through this directly. A higher SHBG with a higher total T can still leave free T relatively unchanged.
- The mechanism is overwhelmingly indirect. The dominant pathway is weight loss and improved insulin sensitivity restoring hypothalamic-pituitary signaling. A direct testicular GLP-1 receptor effect has been hypothesized but is not established as the main driver in humans.
Tirzepatide and testosterone: what the pilot data show
Tirzepatide's dual GIP and GLP-1 mechanism produces larger average weight loss than pure GLP-1 agonists, which raises the obvious follow-up question — does the testosterone signal scale with the weight loss? The 2025 controlled pilot study in Reproductive Biology and Endocrinology on the short-term impact of tirzepatide on metabolic hypogonadism and body composition (PMID 40604795) was designed to look at exactly that question.
Pilot studies do not settle questions, but they shape the next round of trials. Three patterns emerge from the tirzepatide and broader GLP-1 literature that are worth tracking:
- Improvement is real but variable. Some men normalize testosterone with weight loss alone. Others do not.
- Late responders exist. The 2026 Minerva Endocrinologia pilot on testosterone undecanoate added to tirzepatide in late responders (PMID 41801155) studied 10 obese men who had blunted testosterone recovery on tirzepatide alone. The fact that the study exists at all signals that clinicians regularly see incomplete normalization.
- Body composition often shifts even when total testosterone is slow to move. Visceral fat reduction, lean-mass preservation under appropriate protein intake, and improved insulin sensitivity can drive symptomatic improvement on a different timeline than the labs.
None of this is approval-grade evidence to prescribe tirzepatide for hypogonadism. It is hypothesis-generating data that supports the upstream framing — fix the metabolic state and the hormones often, but not always, follow.
Do I still need TRT if I'm on a GLP-1?
That is a clinical question your prescriber is best positioned to answer, but the framework most commonly used in the published reviews looks like this. Three patterns are common.
Pattern 1: GLP-1 alone resolves the picture
A man with obesity, BMI in the high 30s, total testosterone in the low 200s ng/dL, normal-to-low LH, and classic functional-hypogonadism symptoms starts a GLP-1 receptor agonist for weight management or type 2 diabetes. Over 6 to 12 months he loses 15 to 20 percent of body weight. Repeat labs show total testosterone in the high 300s or 400s ng/dL, A1C improved, lipids improved, symptoms partially or fully resolved. TRT is often not started. This is the population the 2025 meta-analyses describe most cleanly.
Pattern 2: GLP-1 helps but is not enough
Same starting point, same meaningful weight loss, but testosterone stays in the low-normal range and symptoms persist. The 2026 Minerva Endocrinologia pilot population (PMID 41801155) sits here. In this pattern, prescribers may add testosterone replacement after weight has stabilized and a repeat labs cycle confirms the gap. The decision is clinical, not algorithmic.
Pattern 3: TRT first, GLP-1 added later
A man already on TRT for documented hypogonadism gains weight or develops type 2 diabetes. A GLP-1 receptor agonist is added for the metabolic indication. Testosterone may rise further (or stay the same), SHBG often rises, and the prescriber re-titrates the testosterone dose using the new free-T context. This is the population where the TRT blood work schedule matters most because two variables are moving simultaneously.
Why the order matters. Starting both medications in the same month makes attribution impossible. If your prescriber has the option, sequencing — GLP-1 first with re-evaluation after meaningful weight loss, or TRT first if symptoms are severe — yields cleaner data and clearer next steps.
Combining GLP-1 and TRT: what to discuss with your prescriber
If your clinical situation points toward both classes, the published reviews and standard monitoring guidelines (2018 Endocrine Society JCEM guideline, Bhasin et al.; 2018 AUA testosterone deficiency guideline, Mulhall et al.) outline several practical questions:
- Sequencing. Is it reasonable to start the GLP-1 first and re-evaluate testosterone at 3 to 6 months, or are symptoms severe enough that TRT should not wait?
- Baseline labs. Have we run a complete pre-TRT panel (total T x2 morning draws, free T or SHBG-based calc, LH, FSH, sensitive estradiol, prolactin, CBC with hematocrit, CMP, lipids, A1C, PSA in men 40+) before any decision?
- Goals. Are we treating the metabolic disease, the symptoms of low T, fertility, body composition, or all of the above? The order matters.
- Re-evaluation timing. When will labs be repeated, and what threshold of weight loss or symptom change triggers a treatment change?
- Fertility. If fertility is on the table, has HCG, clomiphene, or enclomiphene been considered before exogenous testosterone? See the companion piece on peptides vs TRT for how adjuncts factor in.
- Discontinuation plan. If meaningful weight loss restores testosterone, is there a plan to re-evaluate the need for ongoing TRT? See coming off TRT for what HPTA recovery looks like.
Side effects and monitoring overlap
Both drug classes have monitoring profiles. They overlap on cardiovascular and metabolic markers, and they each have class-specific watch-list items. The two profiles below summarize what prescribers commonly track.
What GLP-1 prescribers monitor
- Gastrointestinal symptoms — nausea, vomiting, constipation, diarrhea, especially during dose escalation.
- Pancreatitis signal — severe, persistent abdominal pain warrants prompt evaluation.
- Gallbladder disease — rapid weight loss raises gallstone risk; right-upper-quadrant pain warrants evaluation.
- Hypoglycemia risk — low when used alone; higher when combined with insulin or sulfonylureas.
- Renal function — particularly with volume loss from prolonged GI symptoms.
- Thyroid C-cell labeling — boxed-warning context per US labeling for medullary thyroid carcinoma signal in animal studies.
What TRT prescribers monitor
- Hematocrit — intervention threshold around 54 percent per Endocrine Society 2018; see hematocrit on TRT.
- Sensitive estradiol — LC-MS/MS assay; see estradiol on TRT.
- PSA and prostate exam timing — baseline, 3-12 months, then annual per AUA 2018.
- Cardiovascular markers — blood pressure, lipids, with the TRAVERSE trial (Lincoff AM et al., NEJM 2023) signals on pulmonary embolism and atrial fibrillation as ongoing context.
- Sleep apnea screening — particularly with a high-BMI starting point; see TRT and sleep apnea.
The combined monitoring picture at a glance
| Marker | Why it's tracked on GLP-1 | Why it's tracked on TRT |
|---|---|---|
| Hematocrit | Not a class concern | Threshold ~54% per Endocrine Society 2018 / AUA |
| Sensitive estradiol (LC-MS/MS) | Indirect: weight loss reduces aromatization | Direct: aromatization of exogenous testosterone |
| SHBG | Often rises with weight loss and improved insulin sensitivity | Drives the calculated free-T number |
| A1C / fasting glucose | Primary efficacy marker | Tracks metabolic comorbidity |
| Lipids | Improvement with weight loss | Cardiovascular surveillance per AUA 2018 |
| PSA | Not a class concern | Baseline, 3-12 months, then annual per AUA 2018 |
| Lipase / GI symptoms | Pancreatitis signal | Not a class concern |
| Body weight, waist | Primary efficacy marker | Tracks metabolic comorbidity and aromatization risk |
Where the two profiles overlap
Cardiovascular and metabolic markers — A1C, fasting glucose, lipid panel, blood pressure, body weight, waist circumference, liver enzymes — are tracked by both classes. SHBG often shifts with weight loss, which changes the calculated-free-T number even when the dose has not changed. Reading TRT labs without controlling for SHBG drift on a GLP-1 is one of the most common ways prescribers and patients get confused. The Tandfonline 2025 review (DOI 10.1080/13685538.2025.2601423) is the clearest published walk-through of this dynamic.
Fertility, spermatogenesis, and the GLP-1 angle
Exogenous testosterone suppresses pituitary LH and FSH, which suppresses intratesticular testosterone and spermatogenesis. That is the central reason men trying to conceive are often steered toward enclomiphene, clomiphene, or HCG instead of, or alongside, TRT.
GLP-1 receptor agonists are a different conversation. The 2025 Diabetes, Obesity and Metabolism study on semaglutide and sperm morphology in obese men with type 2 diabetes and functional hypogonadism (PMID 39511836) reported improvements in sperm morphology in this population — consistent with the broader pattern that fixing the metabolic state often helps the reproductive picture. That is an associative finding in a specific population, not a fertility indication.
Counter-signals exist. A 2025 International Journal of Impotence Research analysis on prescribing semaglutide for weight loss in non-diabetic obese patients (PMID 38778151) reported an association with increased risk of erectile dysfunction. The mechanism is not established. Population-based associations do not equal causation, but they are part of why the published reviews stop short of recommending GLP-1s as a fertility intervention.
Pro tip — fertility and timing. If conception is on the near-term horizon, the conversation with your prescriber is not just GLP-1 versus TRT. It is also whether to use HCG, clomiphene, or enclomiphene as the testosterone-supportive arm so that spermatogenesis is preserved during the period you are trying to conceive.
What the data do not answer yet
Honest framing of the evidence base requires naming the gaps. Several things the current literature cannot resolve:
- Long-term combination outcomes. Multi-year cardiovascular, prostate, and fertility outcomes for men on GLP-1 plus TRT have not been studied in a dedicated randomized trial. Inferences pull from each class separately.
- Whether GLP-1-driven testosterone normalization is durable. If a man stops the GLP-1 and weight regains, does the testosterone fall back? Pilot data hint yes; rigorous trials are not yet published.
- Whether tirzepatide is meaningfully better than semaglutide for testosterone specifically. Tirzepatide appears to drive larger weight loss; whether the testosterone signal is proportionally larger or only weight-mediated is unsettled.
- Direct testicular receptor effects. Whether GLP-1 receptor activation has a meaningful direct effect on Leydig cells in human men — beyond the weight-loss-mediated pathway — remains an open mechanistic question discussed in the 2025 Andrology and 2026 Andrology systematic reviews.
- Lean men. The testosterone signal is in men with obesity. Lean, eugonadal men should not assume the same effects apply.
The bottom line
GLP-1 receptor agonists and testosterone replacement therapy can coexist in the same treatment plan, and in men with obesity-related metabolic hypogonadism they often address different facets of the same underlying problem. The 2025 BMC Urology meta-analysis (Orra et al.), the 2025 Andrology systematic review (Salvio et al.), the 2025 tirzepatide pilot in Reproductive Biology and Endocrinology, and the 2025 Tandfonline male hormone reset review converge on the same direction of effect — modest weight-loss-mediated testosterone improvement on GLP-1 therapy, with high between-study variability and important late-responder caveats.
That converging signal is not a clinical recommendation. It is the published context for a conversation with your prescriber. Whether you should be on a GLP-1, on TRT, on both in some sequence, or on neither is a decision driven by your weight, glycemic status, baseline labs, symptoms, fertility goals, comorbidities, and the prescriber's judgment — not by an article on the internet.
The good news is that the framing has shifted. Treating low testosterone in men with obesity used to be a single-lever decision: TRT or no TRT. The published evidence in 2025 and 2026 makes the upstream lever — metabolic state — clinically actionable in a way it was not five years ago. That is a better starting point for the next conversation with your physician.
Frequently Asked Questions
Can you take Ozempic with TRT?
There is no published prescribing-information contraindication between semaglutide (Ozempic, Wegovy) and testosterone replacement therapy, and clinicians do co-prescribe them in men with obesity, type 2 diabetes, and low testosterone. The 2025 BMC Urology meta-analysis (Orra et al., PMID 41291666) and the 2025 Andrology systematic review (Salvio et al., PMID 40105090) both reviewed GLP-1 receptor agonist effects on male hormones without identifying a safety signal specific to combination with testosterone. That is not a clinical recommendation — combination therapy is a decision made by a prescriber who has your full history, weight, glycemic status, and labs in front of them.
Does semaglutide raise testosterone?
The evidence to date suggests semaglutide and other GLP-1 receptor agonists are associated with modest increases in total testosterone in men with obesity, primarily through weight loss and improved insulin sensitivity rather than a direct testicular mechanism. The 2025 BMC Urology meta-analysis (Orra et al., PMID 41291666) and the 2026 Journal of Sexual Medicine review (PMID 41498523) both report increases in total testosterone after GLP-1 therapy in men with obesity. The magnitude varies widely between studies and individuals; semaglutide is not a substitute for testosterone replacement when testosterone is clinically low and symptoms persist.
Does tirzepatide increase testosterone?
A 2025 controlled pilot study in Reproductive Biology and Endocrinology (PMID 40604795) reported that short-term tirzepatide therapy in men with obesity and metabolic hypogonadism was associated with improvements in body composition and testosterone, consistent with the broader pattern observed for GLP-1 receptor agonists. A separate 2026 pilot in Minerva Endocrinologia (PMID 41801155) examined adding testosterone undecanoate to tirzepatide in men who were late responders, suggesting clinicians do see incomplete testosterone normalization on tirzepatide alone. Pilot studies are hypothesis-generating, not definitive, and tirzepatide is not approved for treating hypogonadism.
Do I need TRT if I take a GLP-1?
It depends on whether your low testosterone is metabolic (driven by obesity and insulin resistance, often called functional or secondary hypogonadism) or primary, and on your symptoms. In some men with obesity-related metabolic hypogonadism, sustained weight loss on a GLP-1 receptor agonist can normalize testosterone over months to a year. In others, testosterone remains low even after meaningful weight loss — which is the late-responder pattern described in the 2026 Minerva Endocrinologia tirzepatide pilot. Your prescriber decides based on repeat labs, symptoms, and shared decision-making.
Is it safe to combine GLP-1 and testosterone?
There is no labeled drug-drug interaction between testosterone esters (cypionate, enanthate, undecanoate, gels, pellets) and GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide). The 2025 Andrology systematic review (Salvio et al., PMID 40105090) and 2025 BMC Urology meta-analysis (Orra et al., PMID 41291666) did not flag a co-administration safety concern. Both classes have their own monitoring profiles — pancreatitis and gallbladder symptoms for GLP-1s; hematocrit, sensitive estradiol, PSA, lipids, and blood pressure for TRT (per the 2018 Endocrine Society and AUA guidelines). Combination therapy is a clinical judgment call.
Will a GLP-1 affect my TRT blood work?
GLP-1 receptor agonist therapy can change several markers that overlap with the TRT panel: A1C and fasting glucose typically improve, lipids often improve, body weight and waist circumference fall, and SHBG can rise as insulin resistance falls — which mathematically lowers calculated free testosterone even when total testosterone climbs. The 2025 Andrology review (Salvio et al., PMID 40105090) and Tandfonline 2025 male hormone reset review (DOI 10.1080/13685538.2025.2601423) both discuss SHBG dynamics on weight loss. Interpret labs with your prescriber rather than chasing a single number.